The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
6-(5-Fluoro-2-((5-((4-isopropylpiperazin-1-yl)methyl)pyridin-2-yl)amino)pyrimidin-4-yl)-1-isopropyl-3,4-dihydroquinolin-2(1H)-one ID: ALA5195801
PubChem CID: 168287640
Max Phase: Preclinical
Molecular Formula: C29H36FN7O
Molecular Weight: 517.65
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: CC(C)N1CCN(Cc2ccc(Nc3ncc(F)c(-c4ccc5c(c4)CCC(=O)N5C(C)C)n3)nc2)CC1
Standard InChI: InChI=1S/C29H36FN7O/c1-19(2)36-13-11-35(12-14-36)18-21-5-9-26(31-16-21)33-29-32-17-24(30)28(34-29)23-6-8-25-22(15-23)7-10-27(38)37(25)20(3)4/h5-6,8-9,15-17,19-20H,7,10-14,18H2,1-4H3,(H,31,32,33,34)
Standard InChI Key: JZDWVQHSMXIBOJ-UHFFFAOYSA-N
Molfile:
RDKit 2D
38 42 0 0 0 0 0 0 0 0999 V2000
-2.1417 1.6491 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.4270 2.0614 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.7151 1.6494 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.7151 0.8243 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.4252 0.4125 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.1417 0.8206 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.0005 0.4117 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.7140 0.8243 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.7141 1.6495 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.4270 2.0602 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1419 1.6475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1435 0.8264 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.4317 0.4099 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.8563 2.0616 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.5709 1.6491 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.5709 0.8238 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.2855 0.4113 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.0001 0.8239 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-5.0001 1.6491 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.2855 2.0616 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.8565 2.0601 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
-5.7148 0.4113 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-6.4295 0.8239 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.8582 0.4138 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.5730 0.8262 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.2851 0.4142 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.2851 -0.4111 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.5748 -0.8231 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.8582 -0.4148 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.9999 0.8269 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.7148 0.4141 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.7148 -0.4112 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.9999 -0.8238 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.9999 -1.6491 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.7146 -2.0616 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.2853 -2.0616 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.4295 -0.8238 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-5.7148 -0.4138 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 1 0
4 3 2 0
5 4 1 0
1 6 1 0
6 5 2 0
4 7 1 0
7 8 1 0
9 8 2 0
10 9 1 0
11 10 2 0
12 11 1 0
13 12 2 0
8 13 1 0
1 14 1 0
14 15 1 0
16 15 1 0
17 16 1 0
18 17 1 0
19 18 1 0
20 19 1 0
15 20 1 0
11 21 1 0
18 22 1 0
22 23 1 0
12 24 1 0
25 24 2 0
26 25 1 0
27 26 2 0
28 27 1 0
29 28 2 0
24 29 1 0
26 30 1 0
31 30 1 0
32 31 1 0
33 32 1 0
27 33 1 0
33 34 1 0
34 35 1 0
34 36 1 0
32 37 2 0
22 38 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 517.65Molecular Weight (Monoisotopic): 517.2965AlogP: 4.63#Rotatable Bonds: 7Polar Surface Area: 77.49Molecular Species: NEUTRALHBA: 7HBD: 1#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): 1#RO5 Violations (Lipinski): 1CX Acidic pKa: 10.29CX Basic pKa: 8.21CX LogP: 4.46CX LogD: 3.59Aromatic Rings: 3Heavy Atoms: 38QED Weighted: 0.49Np Likeness Score: -1.48
References 1. Chen W, Ji M, Cheng H, Zheng M, Xia F, Min W, Yang H, Wang X, Wang L, Cao L, Yuan K, Yang P.. (2022) Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer., 65 (22.0): [PMID:36350721 ] [10.1021/acs.jmedchem.2c00947 ]